Mineralys Therapeutics Inc [MLYS] stock is trading at $14.21, up 1.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MLYS shares have gain 5.03% over the last week, with a monthly amount drifted -10.52%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.
Mineralys Therapeutics Inc [MLYS] stock has fluctuated between $8.24 and $18.38 over the past year. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $14.21 at the most recent close of the market. An investor can expect a potential return of 195.57% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -0.68 and Total Capital is -1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.80 points at the first support level, and at 13.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.55, and for the 2nd resistance point, it is at 14.89.
Ratios To Look Out For
For context, Mineralys Therapeutics Inc’s Current Ratio is 14.02. In addition, the Quick Ratio stands at 14.02 and the Cash Ratio stands at 7.79.
Transactions by insiders
Recent insider trading involved Slingsby Brian Taylor, Director, that happened on Mar 13 ’25 when 0.26 million shares were purchased. Chief Medical Officer, Rodman David Malcom completed a deal on Apr 14 ’25 to sell 11366.0 shares. Meanwhile, CFO and Secretary Levy Adam Scott sold 10757.0 shares on Apr 11 ’25.
